Acceleron had rounded up $30 million in second-round venture capital to help fund drug development work. Its lead candidate is ACE-011, an experimental therapy for bone loss that is now in early-stage clinical trials. Other therapies in the pipeline include therapies for cancer, musculoskeletal and metabolic diseases. OrbiMed Advisors led the round.
- here's the report on Acceleron from the Boston Business Journal